Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma

25 Oct 2021

Abstract excerpt

Abstract Background Glioblastoma (GBM) has a devastating median survival of only one year. Treatment includes resection, radiation therapy, and temozolomide (TMZ); however, the latter increased median survival by only 2.5 months in the pivotal study. A desperate need remains to find an effective treatment. Methods We used the Connectivity Map (CMap) bioinformatic tool to identify candidates for repurposing based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34696786
DOI: 10.1186/s13046-021-02135-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for GlioblastomaPMID 34696786Read ↗

Identification of new targets for glioblastoma therapy based on a DNA expression microarraySemantic proximity Read ↗

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.Semantic proximity Read ↗

Repurposing of CNS accumulating drugs Gemfibrozil and Doxylamine for enhanced sensitization of glioblastoma cells through modulation of autophagySemantic proximity Read ↗

Multi-omics and Pharmacological Characterization of Patient-derived Glioma Cell LinesSemantic proximity Read ↗

Identification of potential biomarkers and candidate small molecule drugs in glioblastomaSemantic proximity Read ↗

Integrating Multi-Omics Analysis for Enhanced Diagnosis and Treatment of Glioblastoma: A Comprehensive Data-Driven ApproachSemantic proximity Read ↗

Integrating Multi-Omics Analysis for Enhanced Diagnosis and Treatment of Glioblastoma: A Comprehensive Data-Driven ApproachSemantic proximity Read ↗

An atlas of causal and mechanistic drivers of interpatient heterogeneity in gliomaSemantic proximity Read ↗

Integrative multi-omics combined with functional pharmacological profiling in patient-derived organoids identifies personalized therapeutic vulnerabilities of adult high-grade gliomasSemantic proximity Read ↗

Drug and disease signature integration identifies synergistic combinations in glioblastomaSemantic proximity Read ↗

Identification of Differentially Expressed Genes in Different Glioblastoma Regions and Their Association with Cancer Stem Cell Development and Temozolomide ResponseSemantic proximity Read ↗

Reversal gene expression assessment for drug repurposing, a case study of glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.